Compare WNC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNC | ASMB |
|---|---|---|
| Founded | 1985 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.5M | 512.1M |
| IPO Year | 2009 | 2010 |
| Metric | WNC | ASMB |
|---|---|---|
| Price | $11.76 | $19.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $21.50 | ★ $51.20 |
| AVG Volume (30 Days) | ★ 798.3K | 201.9K |
| Earning Date | 10-29-2026 | 11-24-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,027,489,000.00 | N/A |
| Revenue This Year | $2.31 | N/A |
| Revenue Next Year | $29.64 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $6.63 | $19.20 |
| 52 Week High | $14.55 | $39.71 |
| Indicator | WNC | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 42.68 |
| Support Level | $11.64 | $19.25 |
| Resistance Level | $14.33 | $21.65 |
| Average True Range (ATR) | 0.84 | 1.16 |
| MACD | -0.06 | 0.37 |
| Stochastic Oscillator | 26.90 | 26.65 |
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.